Lexaria Offers Warrant Holders Early Exercise Incentive

Lexaria - Nicotine - Television

KELOWNA, British Columbia, Oct. 27, 2016 /Weed Wire/ — Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) has received approval to offer existing warrant holders an incentive to exercise existing warrants early.

For each existing warrant from the 2015 equity unit financings that is exercised on or before November 30 2016, the placee will receive a second warrant with identical terms to the warrant subscribed for in 2015.

In the case of the May 2015 equity financing, each placee will receive a second warrant to buy one common share of the Company as per the original terms: exercisable at US$0.25 and expiring May 14, 2017.

In the case of the December 2015 equity financing, each placee will receive a second warrant to buy one common share of the Company as per the original terms: exercisable at US$0.30 and expiring Dec 10, 2017.

Only existing warrants that are exercised prior to November 30, 2016 will generate the issuance of a new warrant to replace it. Any existing warrants NOT exercised prior to November 30, 2016 will NOT generate a new replacement warrant. All figures will be adjusted to account for the December 2015 forward stock split.

The securities issued will be subject to a hold period for any resales into the USA under Rule 144, of six months and one day. Up to a total of 6,143,316 warrants qualify for the early exercise incentive. The Private Placement is subject to normal regulatory approvals.

No commissions or placement fees will be paid in the event that any or all of the warrants are exercised. Use of proceeds from any warrants that are exercised will be general corporate purposes.

Separately, the Company has settled an existing US$9,000 debt with a former executive consultant of the firm by issuing 56,250 restricted common shares at an issuance price of US$0.16 per share, as payment in full for the obligation.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria
Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.


Lexaria Bioscience Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: any revenue or license fee payments that may be realized from license agreements, the introduction of any product lines that are derived from license agreements, that license arrangements may be entered into with other companies or partners, that the Company’s technology enables higher rates of absorption of certain molecules such as vitamins and cannabinoids while simultaneously masking and at times even eliminating inherent strong flavors and/or odors typical of those molecules, or that the technology will function in a similar manner if tested with THC, nicotine, or any of the other molecules named in our patent applications. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that any license agreement, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors or as a result of the granted patent. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements, nor that Lexaria’s technology will deliver any improvement in taste or bioavailability with any reliability nor across any product category. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever, nor that any patent application in the USA or any other nation or under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any new definitive agreement will be reached to license the Company’s technology to any third party in return for compensation. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods and ViPovaTM products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Weed Wire disseminates press releases from companies and organizations in the legal marijuana industry. Email weedwire@mjic.com to have your press release added.